A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in HIV Uninfected Adult TB Patients After Treatment Completion
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs ID 93/GLA-SE (Primary)
- Indications Pulmonary tuberculosis
- Focus Adverse reactions
- 28 Feb 2017 Status changed from active, no longer recruiting to completed.
- 30 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.